Tuberculosis treatment adherence and fatality in Spain by Caylà, Joan A et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
Respiratory Research
Open Access Research
Tuberculosis treatment adherence and fatality in Spain
Joan A Caylà*1,2, Teresa Rodrigo1,3, Juan Ruiz-Manzano1,4,10, 
José A Caminero1,5, Rafael Vidal1,6,10, José M García1,7, Rafael Blanquer1,8, 
Martí Casals1,9 and the Working Group on Completion of Tuberculosis 
Treatment in Spain (Study ECUTTE)
Address: 1Programa Integrado de Investigación en Tuberculosis (PII TB) de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR), 
Spain, 2Unidad de Investigación de Tuberculosis de Barcelona, Servicio de Epidemiología de la Agencia de Salud Pública de Barcelona, Barcelona, 
Spain, 3Fundación Respira de la SEPAR, Barcelona, Spain, 4Hospital Universitario Germans Trías y Pujol de Badalona, Badalona, Spain, 5Hospital 
General Universitario de Gran Canaria Dr Negrín, Canary Islands, Spain, 6Hospital Vall D'Hebrón de Barcelona, Barcelona, Spain, 7Hospital San 
Agustín, Avilés, Asturias, Spain, 8Hospital Universitario Dr Peset de Valencia, Valencia, Spain, 9CIBER de Epidemiología y Salud Pública 
(CIBERESP), Barcelona, Spain and 10CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain
Email: Joan A Caylà* - jcayla@aspb.es; Teresa Rodrigo - trodrigo@aspb.es; Juan Ruiz-Manzano - jruizmanzano.germanstrias@gencat.net; 
José A Caminero - jcamlun@gobiernodecanarias.org; Rafael Vidal - ravidal@vhebron.net; José M García - josemaria.garciag@sespa.princast.es; 
Rafael Blanquer - blanquer_raf@gva.es; Martí Casals - mcasals@aspb.es; the Working Group on Completion of Tuberculosis Treatment in Spain 
(Study ECUTTE) - pii_secretaria@separ.es
* Corresponding author    
Abstract
Background: The adherence to long tuberculosis (TB) treatment is a key factor in TB control programs. Always some
patients abandon the treatment or die. The objective of this study is to identify factors associated with defaulting from
or dying during antituberculosis treatment.
Methods: Prospective study of a large cohort of TB cases diagnosed during 2006-2007 by 61 members of the Spanish
Society of Pneumology and Thoracic Surgery (SEPAR). Predictive factors of completion outcome (cured plus completed
treatment vs. defaulters plus lost to follow-up) and fatality (died vs. the rest of patients) were based on logistic regression,
calculating odds ratios (OR) and 95% confidence intervals (CI).
Results: Of the 1490 patients included, 29.7% were foreign-born. The treatment outcomes were: cured 792 (53.2%),
completed treatment 540 (36.2%), failure 2 (0.1%), transfer-out 33 (2.2%), default 27 (1.8%), death 27 (1.8%), lost to
follow-up 65 (4.4%), other 4 (0.3%). Completion outcome reached 93.5% and poor adherence was associated with: being
an immigrant (OR = 2.03; CI:1.06-3.88), living alone (OR = 2.35; CI:1.05-5.26), residents of confined institutions (OR =
4.79; CI:1.74-13.14), previous treatment (OR = 2.93; CI:1.44-5.98), being an injecting drug user (IDU) (OR = 9.51;
CI:2.70-33.47) and treatment comprehension difficulties (OR = 2.93; CI:1.44-5.98). Case fatality was 1.8% and it was
associated with the following variables: age 50 or over (OR = 10.88; CI:1.12-105.01), retired (OR = 12.26;CI:1.74-86.04),
HIV-infected (OR = 9.93; CI:1.48-66.34), comprehension difficulties (OR = 4.07; CI:1.24-13.29), IDU (OR = 23.59;
CI:2.46-225.99) and Directly Observed Therapy (DOT) (OR = 3.54; CI:1.07-11.77).
Conclusion: Immigrants, those living alone, residents of confined institutions, patients treated previously, those with
treatment comprehension difficulties, and IDU patients have poor adherence and should be targeted for DOT. To reduce
fatality rates, stricter monitoring is required for patients who are retired, HIV-infected, IDU, and those with treatment
comprehension difficulties.
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Introduction
Tuberculosis (TB) is an infectious disease requiring adher-
ence to long-term treatment and the tracing of patient's
contacts, thus justifying it being a notifiable disease in
most countries of the world. This ancient disease contin-
ues to be an important public health problem, and for this
reason the World Health Organisation (WHO) declared it
to be a global emergency in 1993 [1]. In 2007 it was esti-
mated that, worldwide, there had been 9.27 million new
cases and 1.756 million deaths from TB, of which 1.37
million cases and 0.456 million deaths were among HIV-
infected individuals[2]. Moreover, to these new cases one
must add the millions already in existence, making it the
most prevalent infectious disease[3].
The rise of immigration over the last decade in Spain has
substantially altered the characteristics of TB patients. The
Spanish population was 45,200,737 inhabitants in 2007,
of whom 4,419,554 (9.99%) were foreign-born[4]. In
Barcelona, a city with one of the highest influxes of immi-
grants, the percentage of foreign-born TB patients rose
from 5% in 1995 to 46% in 2007 (with incidence rates
among immigrants of over 100 cases per 100,000 inhab-
itants) [5].
The Tuberculosis and Respiratory Infections section of
SEPAR (Spanish Society of Pneumology and Thoracic Sur-
gery) has previously published a study on adherence to
anti-tuberculosis treatment and on fatality, referring to a
cohort of patients followed during the period 1999 to
2000[6]. The findings indicated that immigrant status and
being an injecting drug user were associated with worse
treatment adherence, while patients who were HIV-
infected, alcoholics, or of advanced age presented higher
fatality.
The aims of the present study were to analyse antitubercu-
losis treatment adherence and fatality during standard TB
treatments in patients with TB in Spain, and to identify
factors associated with these events. The study will also
permit changes in relation to the earlier study[6] to be
assessed, and to determine whether demographic changes
experienced in Spain due to the considerable rise in immi-
gration have had any influence on adherence to tubercu-
losis treatment.
Methods
A multicentric prospective study was carried out involving
prospective follow-up of an extensive cohort of TB
patients, provided by 61 collaborators from 53 hospitals
throughout Spain. The study was promoted by the Inte-
grated TB Research Programme of SEPAR. Patients diag-
nosed with TB between 1 January 2006 and 31 December
2007, aged 18 years or over, were included. Those patients
with known resistances were excluded, as were those in
whom initiation of standard TB treatment was not advis-
able, such as patients with hepatic problems. Cases were
followed up according to an evaluation calendar (Table
1). An informed consent to participate in the study was
elicited.
The information collected covered the following aspects:
sociodemographic data, toxic habits, clinical history, diag-
nostic methods, drug-susceptibility, medication, clinical
course, and adherence to and outcome of treatment. Data
was collected through an electronic diary made available
through a computerised application, accessed by each
study collaborator via the SEPAR Web site using a person-
alised username and password.
Any patient born outside Spain was classified as an immi-
grant. Men consuming over 280 g of alcohol per week,
and women over 168 g, were considered alcoholics. Intra-
venous users of illegal drugs (heroin and cocaine) were
classified as intravenous drug users (IVDU). Toxicity was
defined as an adverse effect that requires to change at least
one drug, and treatment comprehension was defined as
the perception of the treating doctors of the patient. The
chest X-Rays were performed at the moment of the diag-
nosis and at the 2nd and 6th month and when necessary,
and the evolution was classified by the treating doctor of
the patient as improvement, stable or progression.
During these years the standard treatment for TB in Spain
for new cases were: 2 months of rifampicin (R), isoniazid
(H) and pirazinamide (Z) followed by 4 months of RH
(2RHZ+4RH) or the same treatment plus Ethambutol (E)
during the first 2 months20  (2RHZE+4RH). In Spain
DOTS is a priority only for patients with high risk of bad
adherence (IVDU, homeless, prisoners, etc). A patient was
included in the previous treatment category only if he or
she had taken antituberculosis treatment over one year
before the current active TB episode.
Control of questionnaire completion and the database
was carried out via telephone and e-mail contacts between
the field worker and study collaborators.
The following definitions were employed for treatment
outcome, in accordance with European recommenda-
tions[7]:
Cured: when the patient has completed a full course of
anti-TB therapy and a negative culture is obtained during
the continuation phase (culture-positive patients) or two
negative sputum smears during the continuation phase,
one of which must be at the end of treatment (patients
diagnosed by microscopy).Respiratory Research 2009, 10:121 http://respiratory-research.com/content/10/1/121
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Treatment completed: if the course of treatment prescribed
was completed but no bacteriological conversion
occurred (culture-positive patients) or no smear result is
available at the end of treatment (patients diagnosed by
microscopy).
Default: If the patient interrupts the treatment for any rea-
son for more than two months, if there is a non-comple-
tion of treatment within 9 months when the patient is
placed on a six-month regimen, or if the drug intake was
< 80% of the prescribed dose.
Treatment failure: A patient who fails to achieve bacterio-
logical conversion within 5 months after the start of treat-
ment or, after previous conversion, becomes sputum
smear or culture positive again.
Death: A patient who died of any cause during the course
of treatment is recorded under death.
In the present study, the category of transfer out[7] was
redefined into two subcategories:
Lost to follow-up: when it is known that the patient disap-
peared and no additional information is available.
Transfer out: when a patient moves to another town or
health centre and whose follow-up (with medical report
available) is the responsibility of a doctor not collaborat-
ing in the present study.
The results of the analysis were summarized as:
Successful outcome: the percentage of patients who were
cured or completed treatment out of all those detected.
Completion outcome: the percentage of patients who were
cured or completed treatment out of all patients who were
cured or completed treatment, were defaulters, or were
lost to follow up.
Case-fatality rate: the percentage of patients who died dur-
ing TB treatment out of all patients who were cured or
completed treatment or were defaulters.
Table 1: Patient evaluation calendar
Visit 1
Diagnosis
Visit 2
2 Months
Visit 3 *
6 Months
Criteria of inclusion/exclusion X
Sociodemographic data X
Tobacco, alcohol, drug use X
Anthropometric data XXX
Clinical history X
Diagnostic method employed X
Medication XXX
Clinical course XX
Adherence to treatment XX
Collection of samples XXX
Drug sensitivity test X
Treatment outcome X
Informed consent X
* For long treatments new visits are recommended at 9,12,18 months.Respiratory Research 2009, 10:121 http://respiratory-research.com/content/10/1/121
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Potentially unsatisfactory outcome: the percentage of patients
who interrupted treatment, were lost to follow up, or
failed treatment out of all detected patients.
In accordance with guidelines of the Council for Interna-
tional Organizations of Medical Sciences (CIOMS,
Geneva, 1991), and with recommendations of the Span-
ish Epidemiology Association regarding review of ethical
aspects of epidemiological studies, the present study was
submitted for evaluation to the Research Ethical Commit-
tee of the Teknon Medical Center, Barcelona and was
approved on February 24th, 2006. All records with
patients were identified were confidential and handled in
accordance with the Spanish Data Protection Law 15/
December13th, 1999 (Protección de Datos de Carácter
Personal). Principles of the Helsinki Declaration were fol-
lowed at all times. Each patient had an informed consent
card read aloud to them.
Statistical analysis
A descriptive study was carried out of the qualitative and
quantitative variables collected in order to characterise the
study population. Frequency distributions and medians
for quantitative variables were calculated. Proportions
were compared between groups using χ2 tests, and when
pertinent, the two-sided Fisher test. Quantitative variables
were compared using Student's t-test or its non-parametric
equivalent, the Mann-Whitney U-test, when assumptions
of normality and homogeneity of variances were not met.
Measures of association were calculated using odds ratios
(OR) along with their 95% confidence intervals (CI). The
analysis of factors associated with poor adherence treat-
ment defaulting (comparing: cured plus treatment com-
pleted vs. defaulters plus lost to follow-up) and of fatality
(comparing: died vs. the rest of patients) were analysed
using logistic regression (stepwise method) including in
the model the variables associated at the univariate level
with a p-value < 0.15. A p-value of under 0.05 was consid-
ered significant. The test of Hosmer and Lemeshow was
used to check the goodness-of-fit of the models. Analyses
were conducted using the SPSS statistical package, version
13.0 (SPSS Inc, Chicago, IL, USA).
Results
The number of patients included initially was 1500, how-
ever 10 (0.6%) had to be excluded for not meeting any
inclusion criteria, so the final number of patients analysed
was 1490 (table 2). The majority were males, aged >31
years old, native, occupationally active, lived with their
families, diagnosed via emergency services, had pulmo-
nary TB, either smokers or ex-smokers, initially treated
with three drugs, and who understood well the implica-
tions of having TB and its treatment. They were also char-
acterised by low frequencies of HIV infection, IDU,
alcoholism, previous TB treatment, low levels of drug
resistances, toxicities to drugs, and of treatment via DOT.
Table 2 presents the final outcomes of therapy, where it
may be noted that 89.4% of cases were cured or com-
pleted treatment. It is estimated that 1.8% defaulted, and
4.4% of cases were lost to follow-up and probably did not
complete treatment.
According to these data, the outcome was 'successful' in
89.4% of patients considering all cases and 83.1% consid-
ering only smear-positive cases. Completion was 93.5%
considering all TB cases and 92.4% considering only
smear-positive cases. Among the immigrants, these per-
centages were 87.8 and 88.3, respectively. The outcome of
'potentially unsatisfactory' accounted for 6.3% of all cases
and 7.4% for smear-positive cases.
The analysis of factors possibly associated to poor adher-
ence are presented in table 3. As presented in the table, at
the univariate level poorer adherence was observed for
men, immigrants, younger patients, those not retired,
those not living with their family, HIV-infected patients,
previously treated subjects, those who had difficulty
understanding the treatment, those diagnosed via emer-
gency services, and IDU patients, whereas being in DOT
had no influence. Multivariate analysis confirmed the
influence of being an immigrant, living alone, being resi-
dents of confined institutions, previous TB treatment,
having difficulty understanding the treatment, and being
IDU.
The case-fatality was 1.8%. The analysis of factors associ-
ated with fatality is presented in table 4. Variables having
an influence at the univariate level were: immigrant, disa-
bled or retired, residents of confined institutions or incar-
cerated, HIV-infected, IDU, no radiological improvement,
and being in DOT. Multivariate analysis confirmed the
influence of being aged over 50, being retired, being HIV-
infected, having comprehension difficulties, being IDU,
and having been treated under DOT.
Discussion
In the present study, the completion outcome was 93.5%
and the treatment success outcome was 89.4%, better per-
centages than observed in the previous study conducted
by our group [6]. A study in England, Wales and Northern
Ireland found a treatment success of 79% when calculated
for cases in which outcome information was reported and
62% for all cases[8]. The treatment completion outcome
published by the Barcelona Tuberculosis Control Program
was 95.9%[9]. However, according to several studies,
antituberculosis therapy adherence percentages are varia-
ble: USA[10] (91.2%); San Francisco[11] (88.6%); Nor-
way[12] (83%); Europe[13] (69%) although the way in
which theses percentages are calculated could have some
influence.Respiratory Research 2009, 10:121 http://respiratory-research.com/content/10/1/121
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Table 2: Distribution of patients in terms of study variables.
Variables N (%)
SEX Men 920 (63.4)
Women 532 (36.6)
COUNTRY Immigrant 442(29.7)
Native 1048(70.3)
AGE 18-30 497 (33.4)
31-50 596 (40.0)
>50 397 (26.6)
OCCUPATIONAL STATUS Active 901 (60.5)
Disabled 68 (4.5)
Unemployed 257 (17.2)
Retired 220 (14.8)
Unknown 44 (3.0)
LIVING ARRANGEMENTS Alone 157 (10.5)
Confined institutions 54 (3.6)
Shared accommodation 189 (12.7)
Family 1062 (71.3)
Unknown 28 (1.9)
SOURCE Hospital emergency department 682 (45.8)
Primary Health Care 268 (18.0)
Specialist 210 (14.1)
Unknown 330 (22.1)
HIV-infected No 1060 (71.2)
Yes 66 (4.4)
Unknown 364 (24.4)
INTRAVENOUS DRUG USERS No 872 (58.5)
Yes 21 (1.4)
Unknown 597 (40.1)
LOCALIZATION Pulmonary 1249 (83.8)
Extrapulmonary 159 (10.7)
Mixed 67 (4.5)
Unknown 15 (1.0)
ALCOHOL USE No 1064 (71.4)
Yes 375 (25.2)
Unknown 51 (3.4)
SMOKING Non-smoker 676 (45.4)
Smoker or ex smoker 797 (53.5)
Unknown 17 (1.1)
INITIAL THERAPY 3 Drugs 770 (51.7)
4 Drugs 649 (43.5)
Unknown 71 (4.8)
DRUG RESISTANCE* No 864 (80.1)
Yes 85 (7.9)
Unknown 129 (12.0)
TOXICITY Yes 74 (5.0)
No 1416 (95.0)Respiratory Research 2009, 10:121 http://respiratory-research.com/content/10/1/121
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In our opinion, completion outcome is a better indicator
of adherence than successful outcome because is not
influenced by the number of deaths (sometimes related to
old patients or co morbidities but not to the quality of the
Program). It is therefore essential to unify definition crite-
ria: even though there is agreement over how to calculate
the successful outcome, different methodologies are
employed in calculating completion, making compari-
sons difficult. We consider that the ideal formula for cal-
culating completion outcomes is that used in the present
study (percentage of patients who were cured or com-
pleted treatment out of all patients who were cured or
completed treatment, were defaulters, or were lost to fol-
low-up). Furthermore, we believe it would be important
to add the category 'lost to follow-up' to the European def-
inition when it is known that the patient disappeared and
no additional information is available, only considering
as 'transfer out' a patient who moves to another town or
changes to another health centre and whose follow-up is
performed by some other physician not collaborating in
the study.
Several risk factors of poor adherence have already been
identified in other studies (residents of confined institu-
tions, incarcerated, IDU, previous antituberculosis treat-
ment, HIV-infected and immigrant) [8,14]. In our earlier
study[6], the variables found to be associated were IDU
and immigration while sex, age, and residents of confined
institutions, incarceration, DOT or hospitalisation were
not associated. In the present study, IDU and immigrant
status continue to be associated, and we have also
detected the influence of living alone, being residents of
confined institutions, having difficulty understanding the
treatment, and having previously undergone antiTB treat-
ment. Sex, age group, occupational status, HIV status and
having been diagnosed via emergency department had no
influence. It is worth stressing the importance of not living
with a family and the initial assessment made by the clini-
cian in relation to the ease with which the patient compre-
hends the treatment. Many of those having difficulty
understanding the treatment were immigrants, although
some were native patients.
The case-fatality rate is low compared with other stud-
ies[15] due to the fact that in our study one of the criteria
for exclusion was non-applicability of standard treatment
for whatever reason (known resistances, various types of
co morbidity), and also due to the fact that the frequency
of HIV-infected patients with neoplasms or of advanced
age was relatively low. In an European study, it was
observed that advancing age and resistance to isoniazid
and rifampicin were the strongest determinants of death,
while male sex, European origin, pulmonary site of dis-
ease and previous anti-TB treatment were weaker predic-
tors[16]. In an inner-city cohort, underlying illnesses such
as diabetes mellitus, renal failure, chronic obstructive pul-
monary disease, and HIV infection were predictors of
death[17]. In Mexico, predictors of death included delays
in treatment after onset of the disease and low adherence
of patients to the treatment regime[18].
In our first study, the variables found to be predictive of
fatality were alcoholism, HIV infection and age >64 years,
whereas sex, IDU, residents of confined institutions, DOT
PREVIOUS TREATMENT Yes 131 (9.0)
No 1320 (91.0)
DIRECTLY OBSERVED TREATMENT No 1338 (89.8)
Yes 152 (10.2)
TREATMENT COMPREHENSION Easy 1266 (85.0)
Difficult 139 (9.3)
Unknown 85 (5.7)
FINAL OUTCOME Cured 792 (53.2)
Completed treatment 540 (36.2)
Failure 2 (0.1)
Transfer out 33 (2.2)
Default 27 (1.8)
Death 27 (1.8)
Lost to follow up 65 (4.4)
Other 4 (0.3)
*Only patients with positive culture
Table 2: Distribution of patients in terms of study variables. (Continued)Respiratory Research 2009, 10:121 http://respiratory-research.com/content/10/1/121
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Table 3: Analysis of factors associated with poor adherence to antituberculosis treatment.
UNIVARIATE ANALYSIS (p ≤ 0.05) MULTIVARIATE ANALYSIS (p ≤ 
0.05)
Variables N (%defaulters) p-value OR 95%CI p-value OR 95%CI
SEX Men 880 (7.5) 0.015 1.87 1.13 - 3.09
Women 506 (4.2) 1
COUNTRY Immigrant 420 (12.1) < 0.001 3.24 2.11 - 4.98 0.031 2.03 1.06 - 3.88
Native 1004 (4.1) 1 1
AGE 18-30 479 (8.1) 0.019 2.08 1.12 - 3.83
31-50 578 (6.6) 0.109 1.65 0.89 - 3.04
> 50 367 (4.1) 1
OCCUPATIONAL 
STATUS
Active 876 (6.1) 0.028 3.17 1.13 - 8.86
Disabled 61 (8.2) 0.031 4.39 1.14 - 16.92
Unemployed 244 (11.1) 0.001 6.12 2.10 - 17.82
Retired 201 (2.0) 1
LIVING 
ARRANGEMENTS
Alone 145 (10.3) < 0.001 3.27 1.74 - 6.16 0.037 2.35 1.05 - 5.26
Confined 
institutions
45 (24.4) < 0.001 9.18 4.30 - 19.62 0.002 4.79 1.74 - 13.14
Sharing accom. 180 (12.2) < 0.001 3.95 2.26 - 6.91 0,263 1,59 0,70-3,62
Family 1029 (3.4) 1 1
HIV-infected Yes 60 (13.3) 0.029 2.40 1.09 - 5.29
Unknown 349 (6.6) 0.697 1.10 0.67 - 1.81
No 1015 (6.0) 1
PREVIOUS 
TREATMENT 
COMPREHENSION
Yes 121 (17.4) < 0.001 3.75 2.20 - 6.30 0.009 2.80 1.29 - 6.08
No 1264 (5.3) 1 1
Difficult 122 (11.5) 0.001 3.60 1.91 - 6.79 0.003 2.93 1.44 - 5.98
Easy 1238 (3.5) 1 1
SOURCE Emergencies 646 (9.0) 0.006 2.76 1.34 - 5.66
Primary Care 261 (3.4) 1
Specialist 203 (4.4) 0.587 1.29 0.50 - 3.33
Other 314 (5.1) 0.338 1.50 0.65 - 3.46
INTRAVENOUS 
DRUG USERS
No 830 (4.5) 1 1
Yes 19 (21.1) 0.003 5.71 1.80 - 18.07 0.001 9.51 2.70 - 33.47
Unknown 575 (8.9) 0.001 2.08 1.34 - 3.23 0.027 2.00 1.08 - 3.72
DIRECTLY 
OBSERVED 
TREATMENT
Yes 140 (7.1) 0.730 1.12 0.57 - 2.22
No 1284 (6.4) 1
Also had no influence at univariate level: resistance, alcohol, smoking, radiology, and localization.
CI: Confidence Interval
OR: Odds ratioRespiratory Research 2009, 10:121 http://respiratory-research.com/content/10/1/121
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and hospitalisation were not. In the present study, the
influence of HIV and of retirement (a "proxy" of older
age) is confirmed, and in addition we identify being aged
over 50, being IDU, difficulties in comprehending the
treatment, and being treated under DOT. In contrast, sex,
immigrant status, sharing accommodation, previous
antituberculosis treatment, radiological evolution, and
alcoholism had no influence. When the two studies are
compared, the distribution by sex, age-group and other
variables are fairly similar, but the percentage of immi-
grants now is steadily increasing, as in other countries of
Europe[19]. In relation to DOT, in the current study only
9.3% of patients were under this treatment, and in general
doctors prioritise DOT for more complicated patients. In
any case, it should be emphasised from analysing the pre-
dictor variables in the present study that the variable of
understanding the treatment is very important not only
for adherence, but also for fatality. Therefore, patients in
whom the clinician observes this difficulty should be can-
didates for DOT and for closer monitoring in general.
In regard to the type of therapy applied, it was observed
that, in line with Spanish recommendations during these
years and given the low rates of primary resistance to iso-
niazid, the majority of native patients had received treat-
ment with three drugs (fixed dose combinations of
rifampicin, isoniazid and pyrazinamide) whereas foreign-
born patients (with a higher proportion of resistance to
isoniazid) were recommended to take four drugs[20], i.e.
adding ethambutol. It has recently been observed that
there is a progressive rise in resistances[21,22] and that
this is particularly the case in the immigrant population,
and hence the use of four drugs has been recommended
in the treatment of incident TB patients[23], in line with
both USA[24] and UK[25] guidelines.
It should be noted that the present study was carried out
by a scientific society of pneumologists, and that a consid-
erable number of collaborators contributed an extensive
cohort of patients. Follow-up of cases was exhaustive,
although they cannot be extrapolated to all TB patients in
Spain since the study involved physicians particularly
motivated by this disease. It is therefore possible that per-
centages of defaulting and of fatality among TB cases in
Spain would be somewhat higher in general. Another lim-
itation of this study is that patients with TB drug resistance
were not included because they can have prior history of
abandonment of TB treatments.
In summary, the percentage of cases coming from foreign
countries is greater than recorded previously[6]. Being an
immigrant, living alone, being residents of confined insti-
tutions, having a history of antiTB treatment, having diffi-
culty in understanding the treatment, and being IDU are
all factors associated with poor adherence. Death was
associated with patients who were: over the age of 50,
retired, HIV-infected, IDU, having difficulty understand-
ing treatment, and being treated according to DOT
(explainable since it is applied above all in the most diffi-
cult patients[26]). Therefore, to improve adherence, spe-
cial care should be taken to treat patients with social
problems (DOT at home, methadone programs even in
prisons, admission to TB DOT centres) [27]. To reduce
fatality, earlier suspicion, diagnosis, and treatment are
necessary, particularly among the elderly and those
patients with comorbidity or immunodepression. Com-
munity health worker intervention[28] and closer moni-
toring is necessary for patients in whom the physician
perceives any difficulty in understanding the treatment
(whether immigrants or native); this would lead not only
to improved adherence, but also to better survival among
these TB patients.
Conclusion
It is important that every city, region or country studies
adherence to TB treatment and its predictive factors. In
our case, this study was performed by a national scientific
society of pneumology and these results can help to
improve the control of TB patients in our country, and in
others.
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La Fe, Valencia); R. Castrodeza (H El Bierzo Ponferrada-León, Ponferrada); 
J.J. Cebrián (H Costa del Sol, Marbella); J. E. Ciruelos (Hospital de Cruces, 
Guetxo); M.L. De Souza (Unidad Prevención y Control Tuberculosis, Bar-Respiratory Research 2009, 10:121 http://respiratory-research.com/content/10/1/121
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Table 4: Analysis of factors associated with dying during the expected treatment period among patients with tuberculosis.
UNIVARIATE ANALYSIS (p ≤ 0.05) MULTIVARIATE ANALYSIS (p ≤ 0.05)
Variables N (%deaths) p-value OR 95%CI p-value OR 95%CI
AGE 18-30 497 (0.2) 1
31-50 596 (0.8) 0.191 4.19 0.48 - 36.03
> 50 397 (5.3) 0.001 27.70 3.71 - 206.86 0.039 10.88 1.12 - 105.01
SEX Men 920 (1.8) 0.965 0.98 0.44 - 2.16
Women 532 (1.9) 1
COUNTRY Immigrant 442 (0.9) 0.099 0.40 0.14 - 1.18
Native 1048 (2.2) 1
OCCUPATIONAL 
STATUS
Active 901 (0.4) 1
Disabled 68 (5.9) < 0.001 14.01 3.42 - 57.34
Unemployed 257 (0.8) 0.516 1.75 0.32 - 9.65
Retired 220 (6.8) < 0.001 16.40 5.39 - 49.95 0.012 12.26 1.74 - 86.04
LIVING 
ARRANGEMENTS
Alone 157 (2.5) 0.399 1.60 0.53 - 4.83
Confined 
institutions
54 (5.6) 0.045 3.61 1.02 - 12.73
Sharing accom. 189 (0.5) 0.279 0.32 0.04 - 2.47
Family 1062 (1.6) 1
HIV-INFECTED Yes 66 (7.6) 0.001 5.71 2.00 - 16.22 0.018 9.93 1.48 - 66.34
Unknown 364 (1.9) 0.499 1.36 0.55 - 3.37
No 1060 (1.4) 1
PREVIOUS 
TREATMENT
Yes 131 (3.8) 0.092 2.34 0.87 - 6.28
No 1320 (1.7) 1
COMPREHENSION Difficult 139 (5.0) < 0.001 7.40 2.71 - 20.21 0.020 4.07 1.24 - 13.29
Easy 1266 (0.7) 1
ALCOHOL USE Yes 375 (2.4) 1
No 1064 (1.5) 0.258 0.621
0.27 - 1.41
INTRAVENOUS 
DRUG USERS
No 872 (2.2)
Yes 21 (9.5) 0.046 4.72 1.02 - 21.74 0.006 23.59 2.46 - 225.99
Unknown 597 (1.0) 1
RADIOLOGICAL 
EVOLUTION
Improvement 982 (0.6) 1
Stable/
progression
294 (3.1) 0.002 5.13 1.81 - 14.55
Unknown 214 (5.6) < 0.001 9.66 3.58 - 26.04
DIRECTLY 
OBSERVED 
TREATMENT
Yes 152 (3.9) 0.044 2.57 1.02 - 6.48 0.038 3.54 1.07 - 11.77
No 1338 (1.6) 1
Also had no influence at univariate level: resistance, smoking, and localization.
CI: Confidence Interval
OR: Odds ratioRespiratory Research 2009, 10:121 http://respiratory-research.com/content/10/1/121
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celona); D. Díaz (Complejo Hospitalario Juan Canalejo, La Coruña); B. 
Fernández (H de Navarra, Pamplona); A. Fernández (H Río Carrión, Palen-
cia); J. Gallardo (H General de Guadalajara, Guadalajara); M. Gallego (Cor-
poración Sanitaria Parc Taulí, Sabadell); C. García (H General Isla 
Fuerteventura, Puerto del Rosario); F.J. García (H Universitario de la Princ-
esa, Madrid); J.A. Gullón (Hospital Universitario de Canarias, La Laguna); M. 
Iglesias (H Marqués de Valdecilla, Santander); M.A. Jiménez (Unidad Preven-
ción y Control Tuberculosis, Barcelona); J.M. Kindelan (H Universitario 
Reina Sofía, Córdoba); J. Laparra (H Donostia-San Sebastián, San Sebastián); 
T. Lloret (H General Universitario de Valencia, Valencia); M. Marín (H Gen-
eral de Castellón, Castellón); J.T. Martínez (H Mutua de Terrasa, Tarrasa); 
E. Martínez (H de Sagunto, Sagunto); A. Martínez (H de La Marina Baixa, 
Villajoyosa); J.F. Medina (H Universitario Virgen del Rocío, Sevilla); C. 
Melero (H 12 de Octubre, Madrid); C. Milà (Unidad Prevención y Control 
Tuberculosis, Barcelona); I. Mir (H Son Llatzer, Palma de Mallorca); M.A. 
Morales (Hospital Cruz Roja Inglesa, Ceuta); V. Moreno (H Carlos III, 
Madrid); L. Muñoz (H Reina Sofía, Córdoba); C. Muñoz (H Clínico Univer-
sitario de Valencia, Valencia); J.A. Muñoz-Calero (H Universitario Central, 
Oviedo); I. Parra (H Universitario Virgen de la Arrixaca, El Palmar); T. Pas-
cual (H de Cabueñes, Gijón); A. Penas (Complejo Hospitalario Xeral-Calde, 
Lugo); J.A. Pérez (H Arnau de Vilanova, Valencia); P. Rivas (H Virgen Blanca, 
León); J. Sala (H Universitario Joan XXIII, Tarragona); M. Sánchez (Unidad 
Tuberculosis Distrito Poniente, Almería); P. Sánchez (H del Mar, Barce-
lona); E. Trujillo (Complejo Hospitalario de Ávila, Ávila); E. Valencia (H Car-
los III, Madrid); A. Vargas (H Universitario Puerto Real, Cádiz); I. Vidal 
(Complejo Hospitalario Juan Canalejo, La Coruña); M. Vizcaya (Complejo 
Hospitalario Universitario de Albacete, Albacete); M. Zabaleta (H de 
Laredo, Laredo); G. Zubillaga (H Donostia-San Sebastián, San Sebastián).
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